Abstract
In the scope of a prospective multi-centre study after neoadjuvant combined chemotherapy (carboplatin, ifosfamide, etoposide, vindesine) and radiotherapy (45 Gy) 40 resection specimens of locally advanced non-small-cell lung cancer were analysed in order to establish reproducible pathological/anatomical results of tumour regression. Resection specimens of 28 squamous cell carcinomas and 12 adenocarcinomas were investigated using serial sections of the primary lesion. The mean age of the patients was 57 years. The results were compared to spontaneous regressive changes in a control group of 50 untreated non-small-cell lung cancers. Marked scarry fibrosis in the region of the former primary tumour, concentric foci of fresh tumour necroses and surrounding foam cell clusters with transition into vascular granulation tissue could be established as characteristic features of therapy-induced tumour regression, whereas untreated carcinomas revealed necroses with adjoining vital tumour tissue. Using a threestep regression system, 3 tumours could be classified as grade I (no or only slight tumour regression), 10 tumours as grade IIA (marked but incomplete tumour regression, more than 10% vital tumour tissue), 20 tumours as grade IIB (less than 10% vital tumour tissue) and 7 tumours as grade III (complete tumour regression without vital tumour tissue). After a median follow-up period of 32.3 months in patients with grade IIB or III tumour regression (“responders”) the median survival time of 27.9 months was found to be significantly longer than in patients with grade I or IIA tumour regression (“non-responders”) with a median survival period of 13.7 months (log-rank test,P=0.020). The resection specimens analysed, which were obtained 7 weeks (on average) after the end of radiochemotherapy, did not show specific changes due to preoperative therapy, but quite characteristic histological alterations in the former tumour area were registered, which had been induced by combined neoadjuvant radiation and chemotherapy. The grade of therapy-induced tumour regression could be shown to be a significant prognostic factor in non-small-cell lung cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Al-Kourainy, Kish J, Ensley J, Tapazoglou E, Jacobs J, Weaver A, Crissman J, Cummings G, Al-Sarraf (1987) Achievement of superior survival for histologically negative versus positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 59:233–238
Becker K, Fink U, Siewert JR, Höfler H (1996) Morphological effects of preoperative chemotherapy in locally advanced adenocarcinoma of the stomach (T3/T4) with EAP (etoposid, Adriamycin, cis-platin). Pathol Res Pract 192:341
Böheim K, Mikuz G, Böheim C (1982) Pathohistologische Veränderungen nach zytostatischer Induktionstherapie mit Methotrexat, Bleomycin und Cis-Platinum. Laryngol Rhinol Otol 61:246–250
Bromley LL, Szur L (1955) Combined radiotherapy and resection for carcinoma of the bronchus. Lancet 1955:937–941
Burkes RL, Ginsberg RJ, Shepherd FA (1992) Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 10:580–586
Dabbs DJ (1993) Mammary ductal foam cells: macrophage immunophenotype. Hum Pathol 24:977–981
Dhom G, Degro S (1982) Therapy of prostatic cancer and histopathologic follow-up. Prostate 3:531–542
Eagan R, Ruud C, Lee R (1987) Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer. Cancer Treat Rep 71:895–900
Edelmann MJ, Gandara DR, Roach M, Benfield JR (1996) Multimodality therapy in stage III non-small cell lung cancer. Ann Thorac Surg 47:669–675
Eiff M von, Geiger A, Wagner W, Rübe C, Klinke V, Thomas M, Loo J van de (1994) Neoadjuvant chemo-/radiotherapy in locally advanced non-small cell lung cancer. In: Rao RS, Deo MG, Sanghvi LD (eds) Proceedings of the 16th International Cancer Congress, Monducci, Bologna 1994. pp 1187–1190
Faber LD, Kittle CF, Warren WT (1989) Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 47:669–677
Fischer HP (1985) Therapieinduzierte Tumorregression — Morphologische Befunde an malignen primären und sekundären Lebertumoren nach hochdosierter regionaler Zytostase. Pathologe 6:16–23
Gerrity RG (1981) The role of monocyte in atherosclerosis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 103:181–190
Green S, Weiss GR (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. West New Drugs 10:243–253
Helpap B, Böcking A, Dhom G, Faul P, Kastendieck H (1985) Klassifikation, histologisches und zytologisches Grading sowie Regressionsgrading des Prostatakarzinoms. Pathologe 6:3–7
Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and PAP. J Histochem Cytochem 29:577–580
Huvos AG, Rosen G, Marcove RC (1977) Primary osteogenic osteosarcoma. Arch Pathol Lab Med 101:14–18
Junker K, Krapp D, Müller KM (1994) Morphological changes in small cell bronchial carcinoma after neoadjuvant chemotherapy. In: Antypas G (ed) Proceedings of the 16th International Cancer Congress, Monducci, Bologna, 1994. pp 133–136
Junker K, Krapp D, Müller KM (1995) Kleinzelliges Bronchialkarzinom nach Chemotherapie — Morphologische Befnde. Pathologe 16:217–222
Kaplan EL, Meier P (1958) Non-parametrics estimation from incomplete observations. J Am Statist Assoc 53:457–481
Klurfeld DM (1985) Identification of foam cells in human atherosclerotic lesions as macrophages using monoclonal antibodies. Arch Pathol Lab Med 109:445–449
Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Ollivier JM, Bonvalot S, Gignoux M (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 73:2680–2686
Mould RF, Williams RJ (1982) Survival of histologically proven carcinoma of the lung registered in the North-West-Thames region. Br J Cancer 40:999–1003
Mountain CF (1986) A new international staging system for lung cancer. Chest [Suppl] 89:225s-232s
Mountain CF (1994) Surgery for stage IIIa-N2 non-small cell lung cancer. Cancer 73:2589–2598
Müller KM, Junker K, Wiethege T (1995) Nichtkleinzellige Bronchialkarzinome — Morphologie, Tumorregression, Molekularpatholgie. Onkologe 1:429–440
Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, Bertoni F, Guerra A, Capanna R, Albisinni U, Galletti S, Gherlinzoni F, Calderoni P, Sudanese A, Baldini N, Bernini M Jaffe N (1985) Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer 56:1515–1521
Pisters KMW, Kris MG, Gralla RJ (1990) Preoperative chemotherapy in stage IIIA non-small cell lung cancer: an analysis of a trial in patients with clinically apparent mediastinal node involvement. In: Salmon SE (ed) Adjuvant therapy of cancer. Saunders, Philadelphia, pp 133–137
Pisters KMW, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N (1993) Pathologic complete response in advanced non-small cell lung cancer following preoperative chemotherapy: implications for the design of future non-small cell lung cancer combined modality trials. J Clin Oncol 11:1757–1762
Roessner A, Krüger KH, Ritter J, Urbanitz D (1986) Zur Morphologie des Ewing-Sarkoms nach primärer Chemotherapie. GBK-Mitteilungsdienst 49:28–33
Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330:153–158
Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of tumor to preoperative chemotherapy. Cancer 49:1221–1230
Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, Atkinson EN, Hong WK (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86:673–680
Rusch VW (1993) Neoadjuvant chemotherapy for stage III lung cancer. Semin Thorac Cardiovasc Surg 5:258–267
Salzer-Kuntschik M, Brand G, Delling G (1983) Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologe 4:135–141
Schaffner T, Taylor K, Bartucci EJ (1980) Arterial foam cells with distinctive immunomorphologic and histologic features of macrophages. Am J Pathol 100:57–80
Sherman D, Strauss G, Schwartz J (1987) Combined modality therapy for regionally advanced stage III non-small cell carcinoma of the lung (NSCLC) employing neo-adjuvant chemotherapy (CT), radiotherapy (RT), and surgery (S). Proc Am Soc Clin Oncol 6:167
Shields TW, Higgins GA, Lawton R (1970) Preoperative X-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma. J Thorac Carciovasc Surg 59:49–61
Skarin A, Jochelson M, Sheldon T (1989) Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 40:266–274
Strauss G, Sherman L, Mathisen D (1988) Concurrent chemotherapy (CT) and radiotherapy (RT) followed by surgery (S) in marginally resectable stage III non-small cell carcinoma of the lung (NSCLC): a Cancer and Leukemia Group B study. Proc Am Soc Clin Oncol 7:203
Sulfaro S, Frustaci S, Volpe R, Barzan L, Comoretto R, Monfardini S, Carbone A (1989) A pathologic assessment of tumor residue and stromal changes after intraarterial chemotherapy for head and neck carcinomas. Cancer 64:994–1001
Thomas M, Macha HN, Rübe C, Loo J van de (1995) Stellenwert der Chemotherapie in der multimodalen Behandlung des nichtkleinzelligen Bronchialkarzinoms. Dtsch Med Wochenschr 120:1627–1630
Thomas M, Eiff M von, Rübe C, Klinke V, Diederich S, Loo J van de (1996) Erfolgreiche multimodale Behandlung eines lokal weit fortgeschrittenen nicht-kleinzelligen Bronchialkarzinoms. Dtsch Med Wochenschr 121:658–662
Weiden P, Piantadosi S (1988) Preoperative Chemoradiotherapy in stage III non-small cell lung cancer (NSCLC): A phase II study of the lung cancer study group (LCSG). Proc Am Soc Clin Oncol 7:197
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Junker, K., Thomas, M., Schulmann, K. et al. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123, 469–477 (1997). https://doi.org/10.1007/BF01192200
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01192200